<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00694213</url>
  </required_header>
  <id_info>
    <org_study_id>IPT1-102</org_study_id>
    <nct_id>NCT00694213</nct_id>
  </id_info>
  <brief_title>Pandemic Influenza Plasmid DNA Vaccines (Needle-Free)</brief_title>
  <official_title>A Phase 1, Double-Blinded Study to Evaluate the Safety, Tolerability, and Immunogenicity of Pandemic Influenza Plasmid DNA Vaccines Administered With the Biojector速 2000 Needle-Free System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial will enroll up to 47 subjects. Qualified normal healthy volunteers will be enrolled
      in the study to receive the vaccine or placebo vaccine. Subjects will receive 2 vaccinations
      with the Biojector速 2000, and will be followed for 6 months to evaluate the safety of and the
      immune system's response to the vaccine. The safety and immune system's response will be
      studied throughout the trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of VCL-IPT1 and VCL-IPM1 administered IM using the Biojector速 2000 in adult subjects.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Influenza-specific immunogenicity of VCL-IPT1 and VCL-IPM1 administered IM using the Biojector速 2000</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VCL-IPM1</intervention_name>
    <description>IM, 0.5 mg/mL, 2 injections, 0 and 21 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VCL-IPM1</intervention_name>
    <description>IM, 1 mg/mL, 2 injections, 0 and 21 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VCL-IPT1</intervention_name>
    <description>IM, 1 mg/mL, 2 injections, 0 and 21 days</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PBS</intervention_name>
    <description>IM, 1 mL, 2 injections, 0 and 21 days</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Phosphate Buffered Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 45 years of age

          -  Able to provide informed consent and be followed for 6 months

        Exclusion Criteria:

          -  No immunomodulatory therapy within the past 6 months

          -  No evidence of immunodeficiency or pregnancy

          -  No laboratory or evidence of clinically significant medical disease

          -  No history of previous pDNA immunization

          -  No influenza immunization within the past 30 days

          -  No blood donations within 30 days of screening visit

          -  No history of bleeding disorder

          -  No use of aspirin and/or anticoagulants within 2 weeks of the administration of the
             investigational vaccines
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Don Guterwill, BS, MT</last_name>
    <role>Study Chair</role>
    <affiliation>Vical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Accelovance</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SNBL</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY at Stonybrook, Stony Brook Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-8153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.vical.com</url>
  </link>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2008</study_first_submitted>
  <study_first_submitted_qc>June 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2008</study_first_posted>
  <last_update_submitted>February 11, 2009</last_update_submitted>
  <last_update_submitted_qc>February 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Don Guterwill, BS, MT, Senior Clinical Project Manager</name_title>
    <organization>Vical Incorporated</organization>
  </responsible_party>
  <keyword>Pandemic Influenza</keyword>
  <keyword>Avian Influenza</keyword>
  <keyword>DNA Vaccines</keyword>
  <keyword>Antibody</keyword>
  <keyword>T Cells</keyword>
  <keyword>HA/NP/M2</keyword>
  <keyword>Biojector</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

